FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077972482> ?p ?o ?g. }

• W2077972482 endingPage "684" @default.
• W2077972482 startingPage "683" @default.
• W2077972482 abstract "Due to increasing incidents of cerebral inflammation, Elan Corporation and American Home Products Corporation have recently announced the decision to terminate the clinical trial of AN1792 vaccine for Alzheimer’s disease (AD). Descriptive reports of the complications experienced in the Phase IIA trial of AN1792, following as little as one dose, have not been released. However, it has been reported that affected patients are recovering following anti-inflammatory drug treatment. Proponents of vaccination therapy attest that the unexpected events of the Phase IIA trial of AN1792 were part of the perceived risk in employing a novel therapeutic treatment. And in the case of treating a disorder as devastating as AD inevitably is, it may be that taking the “chance” with AN1792 was merited. This first open peer commentary to discuss vaccination therapy in AD reemphasizes the need for concerted efforts in approaching the design and initiation of AD therapeutics, and encouragingly, demonstrates the shared viewpoint that promise may lie in future therapeutic trials aimed at manipulating amyloid load in AD. However, there is evidence throughout the commentaries presented here (and in other forums), that there are many aspects of AD vaccination immunotherapy suggesting that we are not yet prepared to move forward with this therapeutic approach in humans. For example, it has been proposed that, although inflammation may be a component of AD vaccination immunotherapy, it is a short-lived phenomena and potentially integral to the eventual benefit of vaccination treatment. This theory is supported by experimental data [12], and human disease indicating, for example, that suppression of certain features of inflammation may unfavorably influence the progression of multiple sclerosis [1] (see Dr. Schenk’ commentary). This is very interesting, however, the role of inflammation associated with AD and with the vaccination-based clearance of amyloid from the" @default.
• W2077972482 created "2016-06-24" @default.
• W2077972482 creator A5006795199 @default.
• W2077972482 creator A5048364336 @default.
• W2077972482 creator A5091204574 @default.
• W2077972482 date "2002-09-01" @default.
• W2077972482 modified "2023-10-14" @default.
• W2077972482 title "AN1792 vaccination immunotherapy in Alzheimer’s disease: the case of a therapy before its time" @default.
• W2077972482 cites W1567490604 @default.
• W2077972482 cites W1839733888 @default.
• W2077972482 cites W1967549235 @default.
• W2077972482 cites W1973231428 @default.
• W2077972482 cites W2001751662 @default.
• W2077972482 cites W2005586302 @default.
• W2077972482 cites W2053232186 @default.
• W2077972482 cites W2058614488 @default.
• W2077972482 cites W2072121798 @default.
• W2077972482 cites W2083067175 @default.
• W2077972482 cites W2165362899 @default.
• W2077972482 doi "https://doi.org/10.1016/s0197-4580(02)00081-7" @default.
• W2077972482 hasPublicationYear "2002" @default.
• W2077972482 type Work @default.
• W2077972482 sameAs 2077972482 @default.
• W2077972482 citedByCount "3" @default.
• W2077972482 crossrefType "journal-article" @default.
• W2077972482 hasAuthorship W2077972482A5006795199 @default.
• W2077972482 hasAuthorship W2077972482A5048364336 @default.
• W2077972482 hasAuthorship W2077972482A5091204574 @default.
• W2077972482 hasConcept C126322002 @default.
• W2077972482 hasConcept C203014093 @default.
• W2077972482 hasConcept C22070199 @default.
• W2077972482 hasConcept C2776624504 @default.
• W2077972482 hasConcept C2777701055 @default.
• W2077972482 hasConcept C2779134260 @default.
• W2077972482 hasConcept C71924100 @default.
• W2077972482 hasConcept C8891405 @default.
• W2077972482 hasConceptScore W2077972482C126322002 @default.
• W2077972482 hasConceptScore W2077972482C203014093 @default.
• W2077972482 hasConceptScore W2077972482C22070199 @default.
• W2077972482 hasConceptScore W2077972482C2776624504 @default.
• W2077972482 hasConceptScore W2077972482C2777701055 @default.
• W2077972482 hasConceptScore W2077972482C2779134260 @default.
• W2077972482 hasConceptScore W2077972482C71924100 @default.
• W2077972482 hasConceptScore W2077972482C8891405 @default.
• W2077972482 hasIssue "5" @default.
• W2077972482 hasLocation W20779724821 @default.
• W2077972482 hasOpenAccess W2077972482 @default.
• W2077972482 hasPrimaryLocation W20779724821 @default.
• W2077972482 hasRelatedWork W1545201378 @default.
• W2077972482 hasRelatedWork W1979560439 @default.
• W2077972482 hasRelatedWork W2599415479 @default.
• W2077972482 hasRelatedWork W2766295945 @default.
• W2077972482 hasRelatedWork W2766329113 @default.
• W2077972482 hasRelatedWork W3165053077 @default.
• W2077972482 hasRelatedWork W3166589558 @default.
• W2077972482 hasRelatedWork W3204138838 @default.
• W2077972482 hasRelatedWork W4225788835 @default.
• W2077972482 hasRelatedWork W4313829841 @default.
• W2077972482 hasVolume "23" @default.
• W2077972482 isParatext "false" @default.
• W2077972482 isRetracted "false" @default.
• W2077972482 magId "2077972482" @default.
• W2077972482 workType "article" @default.